Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutasteride plus combined androgen blockade versus combined androgen blockade in recurrent/metastatic salivary duct carcinoma
NL-OMON58919Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dutasteride in salivary duct carcinoma (SDC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Overall response rate and Duration of response. Started Sep 2022; status: recruiting.
02
Drugs
dutasteride
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NL-OMON58919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58919.